| Symbol | KURA |
|---|---|
| Name | KURA ONCOLOGY, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 12730 HIGH BLUFF DRIVE,SUITE 400, SAN DIEGO, California, 92130, United States |
| Telephone | +1 858 500-8800 |
| Fax | — |
| — | |
| Website | https://www.kuraoncology.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001422143 |
| Description | Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. Additional info from NASDAQ: |
2026-08-14 17:30
New Form SCHEDULE 13G/A - Kura Oncology, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000919574-26-005536 <b>Size:</b> 16 KB
Read more
2026-08-12 20:10
(30% Negative) KURA ONCOLOGY, INC. (KURA) Reports Q3 2026 Financial Results
Read more
2026-08-10 12:32
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity
Read more
2026-08-07 11:30
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-07-27 10:32
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
Read more
2026-07-03 11:30
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-06-22 22:00
Leoni Mollie 🔴 sold 84.9K shares of Kura Oncology, Inc. (KURA) at $9.82 Transaction Date: Jun 18, 2026 | Filing ID: 277780
Read more
2026-06-11 12:02
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05738538 | Expanded Access to Ziftomenib | — | Acute Lymphoblastic Leukemia, With KMT2A Rearrangements | Available | — | — | ClinicalTrials.gov |
| NCT04809233 | Expanded Access to Tipifarnib | — | HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) | Available | — | — | ClinicalTrials.gov |
| NCT06930352 | Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged … | Phase2 | Acute Myeloid Leukemia | Not_Yet_Recruiting | 2026-09-10 | 2027-12-31 | ClinicalTrials.gov |
| NCT07355335 | Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML | Phase1 | KMT2A-rearranged | Not_Yet_Recruiting | 2026-07-09 | 2028-01-01 | ClinicalTrials.gov |
| NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients Wit… | Phase3 | Acute Myeloid Leukemia (AML) | Recruiting | 2025-09-26 | 2031-11-01 | ClinicalTrials.gov |
| NCT06655246 | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Ga… | Phase1 | Gastrointestinal Stromal Tumor (GIST) | Recruiting | 2025-03-27 | 2028-12-01 | ClinicalTrials.gov |
| NCT06376162 | Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refracto… | Phase1 | Relapsed/Refractory KMT2A-r Acute Leukemia | Recruiting | 2025-03-18 | 2027-01-01 | ClinicalTrials.gov |
| NCT06448013 | A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2025-03-07 | 2030-12-31 | ClinicalTrials.gov |
| NCT06397027 | A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and… | Phase1 | Refractory Acute Leukemia | Recruiting | 2024-12-27 | 2030-12-31 | ClinicalTrials.gov |
| NCT06001788 | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Re… | Phase1 | AML | Recruiting | 2024-02-22 | 2027-08-01 | ClinicalTrials.gov |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Phase1 | Solid Tumors With HRAS Alterations | Recruiting | 2023-10-18 | 2027-04-01 | ClinicalTrials.gov |
| NCT05735184 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination… | Phase1 | Acute Myeloid Leukemia | Recruiting | 2023-07-18 | 2030-04-01 | ClinicalTrials.gov |
| NCT05693090 | Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer | Phase1 | NSCLC | Withdrawn | 2023-02-01 | 2027-07-27 | ClinicalTrials.gov |
| NCT04997902 | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic He… | Phase1 | HNSCC | Completed | 2021-12-07 | 2025-08-29 | ClinicalTrials.gov |
| NCT04865159 | Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malig… | Phase1 | Advanced Solid Tumor | Terminated | 2021-05-06 | 2023-05-02 | ClinicalTrials.gov |
| NCT04067336 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leuk… | Phase1 | Advanced Malignant Neoplasm | Active_Not_Recruiting | 2019-09-12 | 2028-10-16 | ClinicalTrials.gov |
| NCT03719690 | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations a… | Phase2 | HRAS Gene Mutation | Completed | 2019-03-15 | 2023-05-02 | ClinicalTrials.gov |
| NCT03051035 | First-in-Human Study of KO-947 in Non-Hematological Malignancies | Phase1 | Advanced Malignant Neoplasm | Terminated | 2017-04-06 | 2020-06-02 | ClinicalTrials.gov |
| NCT02807272 | Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and… | Phase2 | Leukemia, Myelomonocytic, Chronic | Completed | 2017-01-10 | 2020-11-30 | ClinicalTrials.gov |
| NCT02779777 | Tipifarnib in Subjects With Myelodysplastic Syndromes | Phase2 | Myelodysplastic Syndromes | Terminated | 2016-06-01 | 2018-08-28 | ClinicalTrials.gov |
| NCT02464228 | Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lym… | Phase2 | Relapsed or Refractory Peripheral T-Cell Lymphoma | Completed | 2016-02-25 | 2021-03-31 | ClinicalTrials.gov |
| NCT02383927 | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutatio… | Phase2 | Thyroid Cancer | Completed | 2015-05-13 | 2020-12-14 | ClinicalTrials.gov |
Total clinical trials: 22
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Cytarabine (Ara-C) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine (AZA) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Questionnaire Administration | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Multigated Acquisition Scan | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Leukapheresis | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Hydroxyurea | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Echocardiography Test | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Biospecimen Collection | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Tipifarnib | Other | Preclinical | HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) | AVAILABLE | NCT04809233 |
| ziftomenib | Other | Preclinical | Acute Lymphoblastic Leukemia, With KMT2A Rearrangements | AVAILABLE | NCT05738538 |
| Cytarabine (Ara-C) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine (AZA) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06448013 |
| Gemtuzumab | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06448013 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06448013 |
| Adagrasib | Other | Phase PHASE1 | Solid Tumors With HRAS Alterations | RECRUITING | NCT06026410 |
| Cabozantinib | Other | Phase PHASE1 | Solid Tumors With HRAS Alterations | RECRUITING | NCT06026410 |
| Darlifarnib | Other | Phase PHASE1 | Solid Tumors With HRAS Alterations | RECRUITING | NCT06026410 |
| Alpelisib | Other | Phase PHASE1 | HNSCC | COMPLETED | NCT04997902 |
| Tipifarnib | Other | Phase PHASE1 | HNSCC | COMPLETED | NCT04997902 |
| Cytarabine (Ara-C) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine (AZA) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | ACTIVE_NOT_RECRUITING | NCT04067336 |
| Cytarabine (Ara-C) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine (AZA) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Cytarabine (Ara-C) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine (AZA) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Cytarabine (Ara-C) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine (AZA) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Cytarabine (Ara-C) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine (AZA) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Cytarabine (Ara-C) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine (AZA) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Cytarabine (Ara-C) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine (AZA) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| KO-947 | Other | Phase PHASE1 | Advanced Malignant Neoplasm | TERMINATED | NCT03051035 |
| Osimertinib | Other | Phase PHASE1 | NSCLC | WITHDRAWN | NCT05693090 |
| Tipifarnib | Other | Phase PHASE1 | NSCLC | WITHDRAWN | NCT05693090 |
| Tipifarnib | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT04865159 |
| HRAS Detection Assay | Other | Phase PHASE2 | HRAS Gene Mutation | COMPLETED | NCT03719690 |
| Tipifarnib | Other | Phase PHASE2 | HRAS Gene Mutation | COMPLETED | NCT03719690 |
| Tipifarnib | Other | Phase PHASE2 | Relapsed or Refractory Peripheral T-Cell Lymphoma | COMPLETED | NCT02464228 |
| Tipifarnib | Other | Phase PHASE2 | Thyroid Cancer | COMPLETED | NCT02383927 |
| Tipifarnib | Other | Phase PHASE2 | Leukemia, Myelomonocytic, Chronic | COMPLETED | NCT02807272 |
| Tipifarnib | Other | Phase PHASE2 | Myelodysplastic Syndromes | TERMINATED | NCT02779777 |
| ziftomenib | Other | Preclinical | Acute Lymphoblastic Leukemia, With Appropriate Mutations | AVAILABLE | NCT05738538 |
| Tipifarnib | Other | Preclinical | HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) | AVAILABLE | NCT04809233 |
| Fludarabine | Other | Phase PHASE1 | Relapsed/Refractory KMT2A-r Acute Leukemia | RECRUITING | NCT06376162 |
| Cytarabine | Other | Phase PHASE1 | Relapsed/Refractory KMT2A-r Acute Leukemia | RECRUITING | NCT06376162 |
| Ziftomenib | Other | Phase PHASE1 | Relapsed/Refractory KMT2A-r Acute Leukemia | RECRUITING | NCT06376162 |
| Ziftomenib | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06448013 |
| Gemtuzumab | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06448013 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06448013 |
| Alpelisib | Other | Phase PHASE1 | HNSCC | COMPLETED | NCT04997902 |
| Tipifarnib | Other | Phase PHASE1 | HNSCC | COMPLETED | NCT04997902 |
| Azacitidine | Other | Phase PHASE1 | Refractory Acute Leukemia | RECRUITING | NCT06397027 |
| Venetoclax | Other | Phase PHASE1 | Refractory Acute Leukemia | RECRUITING | NCT06397027 |
| Ziftomenib | Other | Phase PHASE1 | Refractory Acute Leukemia | RECRUITING | NCT06397027 |
| imatinib mesylate | Other | Phase PHASE1 | Gastrointestinal Stromal Tumor (GIST) | RECRUITING | NCT06655246 |
| ziftomenib | Other | Phase PHASE1 | Gastrointestinal Stromal Tumor (GIST) | RECRUITING | NCT06655246 |
| Ziftomenib | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Questionnaire Administration | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Multigated Acquisition Scan | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Leukapheresis | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Hydroxyurea | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Echocardiography Test | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Cytarabine | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Bone Marrow Biopsy | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Bone Marrow Aspiration | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Biospecimen Collection | Other | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Quizartinib | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05735184 |
| Cytarabine | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05735184 |
| Daunorubicin | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05735184 |
| Azacitidine | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05735184 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05735184 |
| Ziftomenib | Other | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05735184 |
| Cytarabine (Ara-C) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Daunorubicin | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine (AZA) | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Placebo | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Ziftomenib | Other | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Adagrasib | Other | Phase PHASE1 | Solid Tumors With HRAS Alterations | RECRUITING | NCT06026410 |
| Cabozantinib | Other | Phase PHASE1 | Solid Tumors With HRAS Alterations | RECRUITING | NCT06026410 |
| Darlifarnib | Other | Phase PHASE1 | Solid Tumors With HRAS Alterations | RECRUITING | NCT06026410 |
| Granulocyte colony-stimulating factor | Other | Phase PHASE1 | AML | RECRUITING | NCT06001788 |
| Gilteritinib | Other | Phase PHASE1 | AML | RECRUITING | NCT06001788 |
| Cytarabine | Other | Phase PHASE1 | AML | RECRUITING | NCT06001788 |
| Idarubicin | Other | Phase PHASE1 | AML | RECRUITING | NCT06001788 |
| Fludarabine | Other | Phase PHASE1 | AML | RECRUITING | NCT06001788 |
| Ziftomenib | Other | Phase PHASE1 | AML | RECRUITING | NCT06001788 |
| Ziftomenib | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Blinatumomab | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Methotrexate | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Mercaptopurine | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Vorinostat | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Bortezomib | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| PEG asparaginase | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Mitoxantrone | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Dexamethasone | Other | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Itraconazole | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Midazolam | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Ziftomenib | Other | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Nemvaleukin alfa | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04592653 |
| Nemvaleukin Alfa | DRUG | Phase PHASE2 | Squamous Cell Carcinoma of Head and Neck | COMPLETED | NCT04144517 |
| ALKS 4230 + pembrolizumab | DRUG | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02799095 |
| ALKS 4230 | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03861793 |
| Nemvaleukin Alfa Intravenous Less Frequent Dosing | DRUG | Phase PHASE2 | Cutaneous Melanoma | TERMINATED | NCT04830124 |
| Nemvaleukin Alfa Intravenous | DRUG | Phase PHASE2 | Cutaneous Melanoma | TERMINATED | NCT04830124 |
| Nemvaleukin Alfa Subcutaneous | DRUG | Phase PHASE2 | Cutaneous Melanoma | TERMINATED | NCT04830124 |
| Gemcitabine | DRUG | Phase PHASE3 | Platinum-resistant Ovarian Cancer | TERMINATED | NCT05092360 |
| Topotecan | DRUG | Phase PHASE3 | Platinum-resistant Ovarian Cancer | TERMINATED | NCT05092360 |
| Paclitaxel | DRUG | Phase PHASE3 | Platinum-resistant Ovarian Cancer | TERMINATED | NCT05092360 |
| Pegylated Liposomal Doxorubicin (PLD) | DRUG | Phase PHASE3 | Platinum-resistant Ovarian Cancer | TERMINATED | NCT05092360 |
| Nemvaleukin | BIOLOGICAL | Phase PHASE3 | Platinum-resistant Ovarian Cancer | TERMINATED | NCT05092360 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT03861793 |
| Nemvaleukin and Pembrolizumab Combination | BIOLOGICAL | Phase PHASE3 | Platinum-resistant Ovarian Cancer | TERMINATED | NCT05092360 |
| Mezigdomide | DRUG | Phase PHASE1 | KMT2A-rearranged | NOT_YET_RECRUITING | NCT07355335 |
| Cytarabine (Ara-C) | DRUG | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine (AZA) | DRUG | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Placebo | DRUG | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Questionnaire Administration | OTHER | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Multigated Acquisition Scan | PROCEDURE | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Leukapheresis | PROCEDURE | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Hydroxyurea | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Echocardiography Test | PROCEDURE | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Bone Marrow Biopsy | PROCEDURE | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Bone Marrow Aspiration | PROCEDURE | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Biospecimen Collection | PROCEDURE | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| imatinib mesylate | DRUG | Phase PHASE1 | Gastrointestinal Stromal Tumor (GIST) | RECRUITING | NCT06655246 |
| Gemtuzumab | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT06448013 |
| Adagrasib | DRUG | Phase PHASE1 | Solid Tumors With HRAS Alterations | RECRUITING | NCT06026410 |
| Cabozantinib | DRUG | Phase PHASE1 | Solid Tumors With HRAS Alterations | RECRUITING | NCT06026410 |
| Darlifarnib | DRUG | Phase PHASE1 | Solid Tumors With HRAS Alterations | RECRUITING | NCT06026410 |
| Granulocyte colony-stimulating factor | BIOLOGICAL | Phase PHASE1 | AML | RECRUITING | NCT06001788 |
| Gilteritinib | DRUG | Phase PHASE1 | AML | RECRUITING | NCT06001788 |
| Idarubicin | DRUG | Phase PHASE1 | AML | RECRUITING | NCT06001788 |
| Fludarabine | DRUG | Phase PHASE1 | AML | RECRUITING | NCT06001788 |
| Blinatumomab | DRUG | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Methotrexate | DRUG | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Mercaptopurine | DRUG | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Vorinostat | DRUG | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Bortezomib | DRUG | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| PEG asparaginase | DRUG | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Mitoxantrone | DRUG | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| Dexamethasone | DRUG | Phase PHASE1 | Lymphoblastic Leukemia | RECRUITING | NCT05848687 |
| ziftomenib | DRUG | Phase PHASE1 | Gastrointestinal Stromal Tumor (GIST) | RECRUITING | NCT06655246 |
| Quizartinib | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | RECRUITING | NCT05735184 |
| Cytarabine | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | NOT_YET_RECRUITING | NCT06930352 |
| Daunorubicin | DRUG | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Azacitidine | DRUG | Phase PHASE1 | Refractory Acute Leukemia | RECRUITING | NCT06397027 |
| Venetoclax | DRUG | Phase PHASE3 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT07007312 |
| Osimertinib | DRUG | Phase PHASE1 | NSCLC | WITHDRAWN | NCT05693090 |
| Alpelisib | DRUG | Phase PHASE1 | HNSCC | COMPLETED | NCT04997902 |
| Itraconazole | DRUG | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Midazolam | DRUG | Phase PHASE1 | Advanced Malignant Neoplasm | RECRUITING | NCT04067336 |
| Ziftomenib | DRUG | Phase PHASE1 | KMT2A-rearranged | NOT_YET_RECRUITING | NCT07355335 |
| HRAS Detection Assay | DEVICE | Phase PHASE2 | HRAS Gene Mutation | COMPLETED | NCT03719690 |
| KO-947 | DRUG | Phase PHASE1 | Advanced Malignant Neoplasm | TERMINATED | NCT03051035 |
| Tipifarnib | DRUG | Phase PHASE1 | NSCLC | WITHDRAWN | NCT05693090 |
Total products: 235